MICROFLUIDICS INDUSTRY - IDEX/THINXXS ACQUISITION

The microfluidics industry: the acquisition game

Extracted from: Status of the Microfluidics Industry report – May 2017

OUTLINES:

  • IDEX Health & Science announced the acquisition of thinXXS, a German microfluidic devices manufacturer...
  • Diagnostics, point-of-care and pharmaceutical research will drive the rapidly-expanding microfluidic products industry to a potential value of US$23 billion by 2022.
  • Large diagnostics companies are racing to acquire the most promising microfluidic companies. Meanwhile more and more startups emerge.
  • The industry's swift maturation has profoundly impacted the entire supply chain.

LYON, France – December 20, 2017:  IDEX Health & Science announced at the beginning of December the acquisition of thinXXS, a German microfluidic devices manufacturer. This acquisition follows another one that took place two years ago with the company CIDRA Precision Services. Both acquisitions are allowing IDEX Health & Science to expand its technical know-how from glass to polymer microfluidic devices manufacturing, as well as develop its activities towards the microfluidic consumables business. According to Yole Développement (Yole), the strategy of this leading life sciences company consists of the strengthening of its market positioning concerning optofluidic components as well as the development of new business opportunities towards the point-of-care and veterinary market segments.

IDEX acquisitions are not surprising, explains the market research and strategy consulting company.
“This is not the first acquisition of a microfluidic device manufacturer over the past two years”, comments Sébastien Clerc, Technology & Market Analyst at Yole.“Indeed, in August 2016, veterinary diagnostics company Zoetis acquired Scandinavian Micro Biodevices barely one month after Stratec signed the Sony DADC Biosciences acquisition. This new acquisition from IDEX is part of the microfluidics industry’s maturation that has been observed for a few years now.”

Under a dynamic microfluidic devices market showing a 21% CAGR between 2017 and 2022 to reach almost US$ 6 billion in 2022, the group of leading diagnostic and life sciences companies, including Abbott, Alere, bioMérieux and Roche, is increasingly engaged in the identification of innovative companies and potential M&A . Their strategy is clearly focused on the development of their activities and portfolio.

In its Status of Microfluidics Industry report published this year, Yole highlights the numerous acquisitions that have been taking place over the last few years. With more than 700 companies worldwide, almost 300 million products sold in 2016 (1) , and 4500+ patent publications (2) , the microfluidics market is becoming the playground for a lot of financial movements.

Large diagnostics companies are clearly racing to acquire the most promising microfluidic companies. They usually propose a few, often successful microfluidic solutions within their immense portfolio: Abbott, Alere, bioMérieux, and Roche have all witnessed growth in at least one of their segments, driven by a microfluidic solution. These success stories result from solid industry structuring over the past few years: among the numerous companies developing microfluidic-based products, the most promising ones are often acquired by the large diagnostics companies. This was the case for some of molecular diagnostics’ most innovative players: IQuum and BioFire, and more recently Cepheid and Nanosphere, which were all acquired by much larger companies. In parallel, GenePOC received significant investment from Debiopharm (More on i-micronews.com).

In this attractive context, Yole’s analysts have identified almost US$25 billion in M&A across the microfluidics industry since 2015. This has created a virtuous circle: the most promising/most successful startups are acquired or become large players themselves, and investors are eager to put money into the ever-growing number of newcomers leveraging microfluidic technologies and know-how.

The consulting company Yole proposes a comprehensive technology and market analysis of the microfluidic industry. To discover the content of this report in detail, go to i-micronews.com, Medtech reports section.


In addition MedTech team of Yole invites you to meet its experts during key conferences taking place in 2018:
   • Molecular Medicine Tri-Conference
   • Lab-on-a-chip & Microfluidics Europe

To arrange a meeting, please contact us right now! Contact: Julie Robert.


Acronyms:
CAGR: Compound Annual Growth Rate
M&A: Mergers & Acquisition

Sources:
(1) Status of the Microfluidics Industry report, Yole Développement, 2017  
(2) Microfluidic Technologies for Diagnostic Applications report, KnowMade, part of Yole Group of Companies, 2017 - Including microfluidic technologies for diagnostic applications only.


Connect with us


About the Status of the Microfluidics Industry report:

Newsletter subscription

About Yole Développement